Business profile & competitive position
Gilead Sciences, Inc. operates under the Healthcare sector in the Drug Manufacturers – General industry, which means its core business is discovering, developing, manufacturing, and commercializing prescription medicines. The company’s portfolio historically centers on antivirals, including HIV and hepatitis C therapies, and it has been expanding in oncology and inflammatory diseases.
The reported profitability metrics do not show a currently strong accounting moat: GILD’s trailing net margin is -12.5% and its return on equity is -21.7%. Both figures are negative, meaning the company has posted a net loss over the relevant trailing period and is destroying rather than compounding book equity on a GAAP basis. For a company valued at $210.6 billion, that disconnect tells analysts that the market is pricing in future pipeline and franchise cash flows rather than awarding a premium for today’s margins. The competitive assessment, therefore, cannot rest on current margins or ROE; it must rely on product durability, patent protection, and clinical trial outcomes—notably recent late-stage data for Livdelzi (seladelpar). The low beta of 0.36 does suggest investor perceptions of lower volatility than the overall market, consistent with a large, established pharmaceutical franchise, but that stability is not the same as a profitability-driven moat.
Financial posture
Gilead carries a $210.6 billion market capitalization and trades at $169.83. Its trailing price-to-earnings ratio is -54.8, a direct consequence of negative trailing earnings; a negative P/E multiple is not a valuation premium in the usual sense, but rather a sign that traditional earnings-based valuation is not currently meaningful.
The negative financial posture extends to profitability: net margin -12.5% and ROE -21.7%. Technical positioning, however, is stronger: the stock is above its 50-day EMA of $154.59 and the RSI is 62.9, indicating it has been outperforming its recent average without being deeply overbought. The market is effectively treating Gilead as a cash-flow-compounding pharma name despite the GAAP loss, which is why stories about the $3.28 annual dividend and its sustainability are receiving significant attention. The beta of 0.36 also implies lower systematic risk than the broader market, a common trait for large-cap healthcare stocks. All together, the financial picture is one of a mega-cap defensive name whose near-term accounting earnings do not reflect its strategic value, forcing investors to evaluate it through pipeline progress, free-cash generation, and dividend capacity rather than simple P/E.
Macro & geopolitical exposure
As a Drug Manufacturers – General company, Gilead is exposed to macro forces common to the broader biopharma industry rather than company-specific dynamics.
- Regulation & pricing: FDA approvals, patent reviews, Medicare/Medicaid reimbursement rules, and political pressure on drug pricing can materially affect revenue and margins across the sector.
- Trade policy & supply chain: Active pharmaceutical ingredients, biologics manufacturing components, and finished formulations often move across borders, so tariffs or export restrictions can raise costs or disrupt supply.
- Currency exposure: Global drug sales create foreign-exchange sensitivity; a stronger U.S. dollar can reduce the dollar value of overseas revenue.
- Clinical and competitive risk: Patent cliffs, biosimilar launches, and shifts in treatment standards can quickly reshape market share and pricing power throughout the industry.
- Interest rates & capital markets: Large pharma relies on debt and equity markets for acquisitions and partnership deals, so borrowing costs affect M&A capacity and shareholder returns.
These exposures are grounded in Gilead’s industry classification; the exact magnitude for any single company depends on its geographic revenue mix, manufacturing footprint, and patent estate.
Recent developments
The most recent news flow has a bullish tilt:
- [2026-11-08] – The Top 5 Biotech Stocks I’d Buy Right Now Without Any Hesitation (fool.com). The inclusion signals continued positive retail and growth-oriented interest in the name.
- [2026-11-07] – Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe? (247wallst.com). This headline highlights the central tension in Gilead’s financial narrative: a large dividend commitment while GAAP earnings are negative.
- [2026-11-05] – Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) (businesswire.com). Positive late-stage readouts for Livdelzi underpin pipeline optionality and potential expansion in liver disease.
- [2026-11-05] – Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here’s Why the Streak Looks Safe. (fool.com). The article claims the 11-year dividend-raise track record remains intact, a signal management has enough cash confidence to keep returning capital.
Taken together, the recent developments emphasize two investor debates: dividend sustainability despite negative net income, and clinical success for Livdelzi as a potential growth driver.
Earnings behavior & post-earnings drift
Gilead has delivered a perfect earnings record over the last eight reported quarters, beating consensus estimates 8 out of 8 times (100% beat rate), with an average earnings surprise of 7.7%. The post-earnings tendency has been modestly upward: the average 5-day price move after earnings across those quarters is 0.95%, classified as an “up” drift.
The last four quarters show that beats do not always produce immediate gains:
- 2026-10-29: Actual EPS $2.55 vs. estimate $2.19, a 16.4% surprise. The stock rose 3.06% the next day and 1.18% over the following five days.
- 2026-08-04: Actual EPS -$6.75 vs. estimate -$7.25, a 6.9% beat. The stock fell 2.58% the next day but drifted up 0.38% over the following five days.
- 2026-05-07: Actual EPS $2.03 vs. estimate $1.91, a 6.3% beat. The stock dropped 2.04% the next day and 1.49% over the following five days.
- 2026-02-10: Actual EPS $1.86 vs. estimate $1.81, a 2.8% beat. The stock jumped 5.82% the next day and 3.74% over the following five days.
The pattern is that Gilead reliably clears the official consensus, but the price reaction can still be two-sided. The next report is scheduled for February 9, 2027, after the close, with a current consensus EPS estimate of $1.39. Heading into that print, the stock is above its 50-day EMA and the RSI is 62.9, suggesting positive near-term momentum. Traders watching for post-earnings drift should note that even with a 100% beat rate, the five-day average drift is only slightly positive at 0.95%, and individual quarters have produced both gains and pullbacks.
For a deeper dive into how sell-side and institutional models are modeling Gilead’s pipeline, dividend coverage, and 2027 earnings trajectory, readers should look at the full institutional verdict on the ticker.
Frequently Asked Questions
Why is Gilead’s P/E ratio negative?
Gilead’s trailing P/E is -54.8 because the company reported negative trailing net income, reflected in a net margin of -12.5% and ROE of -21.7%. A negative P/E means standard earnings-based valuation multiples are not useful right now, and investors must rely on other metrics such as cash flow, pipeline value, and dividend capacity.
Has Gilead been beating earnings estimates?
Yes. Over the last eight reported quarters, Gilead has beaten the consensus estimate 8 out of 8 times for a 100% beat rate, with an average positive surprise of 7.7%.
When is Gilead’s next earnings report?
Gilead is scheduled to report next on February 9, 2027, after the market close, with a current consensus EPS estimate of $1.39.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-10-29 | $2.55 | $2.19 | +16.4% | +3.06% | +1.18% |
| 2026-08-04 | $-6.75 | $-7.25 | +6.9% | -2.58% | +0.38% |
| 2026-05-07 | $2.03 | $1.91 | +6.3% | -2.04% | -1.49% |
| 2026-02-10 | $1.86 | $1.81 | +2.8% | +5.82% | +3.74% |
| 2025-10-30 | $2.47 | $2.13 | +16% | - | - |
| 2025-08-07 | $2.01 | $1.96 | +2.6% | - | - |
Previous GILD editions
Get the institutional verdict on GILD
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the GILD verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.